Incyte (0J9P) Share Forecast & Price Target
0J9P Analyst Ratings
Moderate Buy
11Buy11Hold0Sell
Based on 22 analysts giving stock ratings to Incyte in the past 3 months
0J9P Stock 12 Month Forecast
Average Price Target
$134.40▲(12.15% Upside)Based on 22 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $134.40 with a high forecast of $157.00 and a low forecast of $104.00. The average price target represents a 12.15% change from the last price of $119.84.
Past 12 Months12 Month ForecastDec2025Sep2026
High$157.00
Average$134.40
Low$104.00
Highest Price TargetHighest$157.00Average Price Target$134.40Lowest Price TargetLowest$104.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| John Newman | Canaccord Genuity | $152 | buy | 26.84%Upside | Reiterated | 10/30/26 | ||
| Mitchell Kapoor | H.C. Wainwright | $152 | buy | 26.84%Upside | Reiterated | 10/30/26 | ||
| Etzer Darout | Barclays | $139→$143 | buy | 19.33%Upside | Reiterated | 10/30/26 | ||
| Ashwani Verma | UBS | $127 | hold | 5.97%Upside | Reiterated | 10/30/26 | ||
 Chris YuNot Ranked | Morgan Stanley | $119→$116 | hold | -3.20%Downside | Assigned | 10/30/26 | ||
| Gavin Clark-Gartner | Evercore ISI | $125→$127 | hold | 5.97%Upside | Reiterated | 10/30/26 | ||
| Stephen Willey | Stifel Nicolaus | $157 | buy | 31.01%Upside | Reiterated | 10/30/26 | ||
| Michael Schmidt | Guggenheim | $152 | buy | 26.84%Upside | Reiterated | 10/29/26 | ||
| Brian Abrahams | RBC Capital | $114→$117 | hold | -2.37%Downside | Assigned | 10/29/26 | ||
| Jay Olson | Oppenheimer | $120→$144 | buy | 20.16%Upside | Upgraded | 10/29/26 | ||
| Derek Archila | Wells Fargo | $128→$127 | hold | 5.97%Upside | Reiterated | 10/29/26 | ||
| Unknown AnalystNot Ranked | Cantor Fitzgerald | ― | hold | ― | Reiterated | 10/29/26 | ||
| Srikripa Devarakonda | Truist Financial | $115 | hold | -4.04%Downside | Reiterated | 10/27/26 | ||
| Tazeen Ahmad | Bank of America Securities | $140 | buy | 16.82%Upside | Reiterated | 10/26/26 | ||
| Evan Seigerman | BMO Capital | $130 | hold | 8.48%Upside | Reiterated | 10/26/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| John Newman | 10/30/26 | $152 | buy | 26.84%Upside | Reiterated | Canaccord Genuity | ||
| Mitchell Kapoor | 10/30/26 | $152 | buy | 26.84%Upside | Reiterated | H.C. Wainwright | ||
| Etzer Darout | 10/30/26 | $139→$143 | buy | 19.33%Upside | Reiterated | Barclays | ||
| Ashwani Verma | 10/30/26 | $127 | hold | 5.97%Upside | Reiterated | UBS | ||
| Chris YuNot Ranked | 10/30/26 | $119→$116 | hold | -3.20%Downside | Assigned | Morgan Stanley | ||
| Gavin Clark-Gartner | 10/30/26 | $125→$127 | hold | 5.97%Upside | Reiterated | Evercore ISI | ||
| Stephen Willey | 10/30/26 | $157 | buy | 31.01%Upside | Reiterated | Stifel Nicolaus | ||
| Michael Schmidt | 10/29/26 | $152 | buy | 26.84%Upside | Reiterated | Guggenheim | ||
| Brian Abrahams | 10/29/26 | $114→$117 | hold | -2.37%Downside | Assigned | RBC Capital | ||
| Jay Olson | 10/29/26 | $120→$144 | buy | 20.16%Upside | Upgraded | Oppenheimer | ||
| Derek Archila | 10/29/26 | $128→$127 | hold | 5.97%Upside | Reiterated | Wells Fargo | ||
| Unknown AnalystNot Ranked | 10/29/26 | ― | hold | ― | Reiterated | Cantor Fitzgerald | ||
| Srikripa Devarakonda | 10/27/26 | $115 | hold | -4.04%Downside | Reiterated | Truist Financial | ||
| Tazeen Ahmad | 10/26/26 | $140 | buy | 16.82%Upside | Reiterated | Bank of America Securities | ||
| Evan Seigerman | 10/26/26 | $130 | hold | 8.48%Upside | Reiterated | BMO Capital |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Incyte
3 Months
Success Rate20/26 ratings generated profit
77%
Average Return
+9.83%
Copying Michael Schmidt's trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +9.83% per trade.
1 Year
Success Rate19/19 ratings generated profit
100%
Average Return
+31.35%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.35% per trade.
2 Years
Success Rate19/19 ratings generated profit
100%
Average Return
+41.44%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.44% per trade.
0J9P Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 41 | 40 | 40 | 21 | 30 |
| Hold | 28 | 41 | 41 | 29 | 26 |
| Sell | 4 | 3 | 2 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 73 | 84 | 83 | 50 | 56 |
In the current month, 0J9P has received 30 Buy Ratings, 26 Hold Ratings, and 0 Sell Ratings. 0J9P average Analyst price target in the past 3 months is 134.40.
0J9P Financial Forecast
High$3.08
Consensus$1.92
Low$1.47
0J9P Earnings Forecast
Next quarter’s earnings estimate for 0J9P is $1.92 with a range of $1.47 to $3.08. The previous quarter’s EPS was -$3.60. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$1.61B
Consensus$1.54B
Low$1.41B
0J9P Sales Forecast
Next quarter’s sales forecast for 0J9P is $1.54B with a range of $1.41B to $1.61B. The previous quarter’s sales results were $1.56B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0J9P Stock Forecast FAQ
What is GB:0J9P’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte’s 12-month average price target is $134.40.
What is GB:0J9P’s upside potential, based on the analysts’ average price target?
Incyte has 12.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Incyte a Buy, Sell or Hold?
Incyte has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 11 hold ratings and 0 sell ratings.
What is Incyte’s share price target?
The average share price target for Incyte is $134.40. This is based on 22 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $157.00, and the lowest forecast is $104.00. The average share price target represents a 12.15% increase from the current price of $119.84.
What do analysts say about Incyte?
Incyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Street analysts.
How can I buy shares of Incyte?
To buy shares of GB:0J9P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.